BCL2 and B-cell non-Hodgkin lymphoma: In conclusion, the results of our study confirm that R-CHOP is not an appropriate therapeutic choice for “high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements”, and that intensive regimens or DA-EPOCH-R should be preferred, especially for younger patients.